Literature DB >> 9460954

The trapdoor procedure using autogenous cortical and cancellous bone grafts for osteonecrosis of the femoral head.

M A Mont1, T A Einhorn, P D Sponseller, D S Hungerford.   

Abstract

We have reviewed the results of 30 operations performed on 23 patients with Ficat stage-III or stage-IV osteonecrosis of the femoral head in which autogenous cortical and cancellous bone grafting had been performed through a so-called trapdoor made in the femoral head. At a mean of 56 months (30 to 60) after operation 20 of 24 stage-III hips (83%) had a good or excellent result as determined by the Harris hip-scoring system. Two of six stage-IV hips (33%) had good or excellent results. Eighteen of 21 hips (86%) with a combined necrotic angle of 200 degrees had good or excellent clinical results compared with only four of nine hips (44%) with a combined necrotic angle of more than 200 degrees. Six of the eight hips which had fair or poor results were in patients who had received corticosteroids; five of these six hips had lesions with a combined necrotic angle of greater than 200 degrees or were in a late stage (stage IV). There were no perioperative complications. Our results suggest that the trapdoor procedure with autogenous cancellous and cortical bone grafting can be successful in Ficat and Arlet stage-III osteonecrosis of the hip in patients with small- to medium-sized lesions.

Entities:  

Mesh:

Year:  1998        PMID: 9460954     DOI: 10.1302/0301-620x.80b1.7989

Source DB:  PubMed          Journal:  J Bone Joint Surg Br        ISSN: 0301-620X


  40 in total

Review 1.  Osteonecrosis of the Hip: A Primer.

Authors:  Michelle J Lespasio; Nipun Sodhi; Michael A Mont
Journal:  Perm J       Date:  2019

2.  One-stage hip arthroplasty and bone grafting for bilateral femoral head osteonecrosis.

Authors:  Lih-Yuann Shih; Yon-Cheong Wong; Hsin-Nung Shih
Journal:  Clin Orthop Relat Res       Date:  2008-07-22       Impact factor: 4.176

3.  Will a vascularized greater trochanter graft preserve the necrotic femoral head?

Authors:  Dewei Zhao; Benjie Wang; Lin Guo; Lei Yang; Fengde Tian
Journal:  Clin Orthop Relat Res       Date:  2009-11-07       Impact factor: 4.176

4.  A current review of non-vascularized bone grafting in osteonecrosis of the femoral head.

Authors:  Todd P Pierce; Randa K Elmallah; Julio J Jauregui; Shiva Poola; Michael A Mont; Ronald E Delanois
Journal:  Curr Rev Musculoskelet Med       Date:  2015-09

Review 5.  General principles for treatment of femoral head fractures.

Authors:  Vincenzo Giordano; Marcos Giordano; Renato Caravellos Glória; Felipe Serrão de Souza; Paulo di Tullio; Marco Martins Lages; Hilton Augusto Koch
Journal:  J Clin Orthop Trauma       Date:  2017-07-29

6.  The safety and efficacy of combined autologous concentrated bone marrow grafting and low-intensity pulsed ultrasound in the treatment of osteonecrosis of the femoral head.

Authors:  Hajime Mishima; Hisashi Sugaya; Tomokazu Yoshioka; Katsuya Aoto; Hiroshi Wada; Hiroshi Akaogi; Naoyuki Ochiai
Journal:  Eur J Orthop Surg Traumatol       Date:  2016-02-27

7.  Hip osteonecroses treated with calcium sulfate-calcium phosphate bone graft substitute have different results according to the cause of osteonecrosis: alcohol abuse or corticosteroid-induced.

Authors:  Andrzej Sionek; Adam Czwojdziński; Jacek Kowalczewski; Tomasz Okoń; Dariusz Marczak; Marcin Sibiński; Marcin Złotorowicz; Jarosław Czubak
Journal:  Int Orthop       Date:  2018-03-17       Impact factor: 3.075

8.  SAS weekly rounds: avascular necrosis.

Authors:  Thomas W Hamilton; Susan M Goodman; Mark Figgie
Journal:  HSS J       Date:  2009-03-18

9.  Nonvascularized bone grafting defers joint arthroplasty in hip osteonecrosis.

Authors:  Thorsten M Seyler; David R Marker; Slif D Ulrich; Tobias Fatscher; Michael A Mont
Journal:  Clin Orthop Relat Res       Date:  2008-05       Impact factor: 4.176

10.  Management of avascular necrosis of femoral head at pre-collapse stage.

Authors:  Ramesh Kumar Sen
Journal:  Indian J Orthop       Date:  2009-01       Impact factor: 1.251

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.